Management of dysphonia caused by amikacin liposome inhalation in M. avium complex pulmonary disease

Int J Tuberc Lung Dis. 2023 Aug 1;27(11):872-873. doi: 10.5588/ijtld.23.0275.
No abstract available

MeSH terms

  • Amikacin / adverse effects
  • Anti-Bacterial Agents / adverse effects
  • Dysphonia* / drug therapy
  • Humans
  • Liposomes
  • Lung Diseases* / drug therapy
  • Mycobacterium avium Complex
  • Mycobacterium avium-intracellulare Infection* / drug therapy

Substances

  • Amikacin
  • Liposomes
  • Anti-Bacterial Agents